top of page

elecell Co., Ltd. Wins the Grand Prize in the 2024 R&D Special Zone Deep Tech Scale-Up IR Competition, Beating 65 Companies from 19 R&D Special Zones Nationwide.

Nov 26, 2024

elecell

elecell Co., Ltd. was awarded the Grand Prize at the 2024 R&D Special Zone Deep Tech Scale-Up IR Contest, held on November 25, 2024, at Spigen Hall in Gangnam, Seoul.

elecell Co., Ltd. was awarded the Grand Prize at the 2024 R&D Special Zone Deep Tech Scale-Up IR Contest, held on November 25, 2024, at Spigen Hall in Gangnam, Seoul.

Organized by the Ministry of Science and ICT and the R&D Special Zone Promotion Foundation, the competition featured around 60 innovative tech companies from 19 R&D special zones across the country, with 12 finalists advancing to the finals after two rounds of preliminaries.

The evaluation was conducted by 21 experts from investment firms, focusing on business capabilities, models, and growth potential. elecell's recognition as the Grand Prize winner will pave the way for increased investment and infrastructure for global market expansion.


Related News Articles


관련 기사:

1. https://www.yna.co.kr/view/AKR20241125139700017

2. https://v.daum.net/v/20241125220905807


배경.png

Let's talk .

Through this partnership, we can advance biomimetic current-based tissue regeneration and wound healing technologies and share groundbreaking solutions. Learn more about our partnership with Eleccell and join us as we strive to bring the world's first next-generation treatments to market.

Partnerships enable us to advance our biomimetic current-based tissue regeneration and wound healing technologies and distribute cutting-edge solutions. Discover more about partnering with elecell and join us in our mission to advance and deploy the world’s first next-generation therapies.

Let's talk .

Partnerships enable us to advance our biomimetic current-based tissue regeneration and wound healing technologies and distribute cutting-edge solutions. Discover more about partnering with elecell and join us in our mission to advance and deploy the world’s first next-generation therapies.

bottom of page